Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plasma immunoreactive endothelin-1 in primary hyperaldosteronism

F Veglio1, R Melchio, F Rabbia

  • 1Department of Medicine and Experimental Oncology, University of Turin, Italy.

American Journal of Hypertension
|June 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Machine learning applied to ambulatory blood pressure monitoring: a new tool to diagnose autonomic failure?

Journal of neurology·2022
Same author

Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.

High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension·2018
Same author

Familial hyperaldosteronism type III.

Journal of human hypertension·2017
Same author

Subtype Diagnosis of Primary Aldosteronism: Approach to Different Clinical Scenarios.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2015
Same author

Renin and aldosterone measurements in the management of arterial hypertension.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2015
Same author

Orthostatic hypotension in a cohort of hypertensive patients referring to a hypertension clinic.

Journal of human hypertension·2015

Plasma endothelin-1 (ET-1) levels were assessed in primary aldosteronism. This study found no significant differences in ET-1 between patients and healthy subjects, indicating ET-1 is not involved in primary aldosteronism hypertension.

Area of Science:

  • Endocrinology
  • Cardiovascular Physiology
  • Hypertension Research

Background:

  • Primary aldosteronism is a condition characterized by excessive aldosterone production, leading to hypertension.
  • Endothelin-1 (ET-1) is a potent vasoconstrictor implicated in various cardiovascular diseases.
  • The role of ET-1 in the pathophysiology of primary aldosteronism remains unclear.

Purpose of the Study:

  • To evaluate plasma endothelin-1 (ET-1) levels in patients with primary aldosteronism.
  • To investigate the correlation between ET-1 and other vasoactive hormones in primary aldosteronism.
  • To determine the potential involvement of circulating ET-1 in the hypertension associated with primary aldosteronism.

Main Methods:

  • Plasma ET-1 levels were measured in 12 patients with primary aldosteronism (5 adenomas, 7 hyperplasia) and 15 healthy controls.

Related Experiment Videos

  • Measurements included plasma ET-1, renin, aldosterone, catecholamines, arginine-vasopressin, and atrial natriuretic peptide.
  • Statistical analysis was performed to compare ET-1 levels and assess correlations.

    • Main Results:

    • No significant differences in plasma ET-1 levels were observed between primary aldosteronism patients (adenoma or hyperplasia) and healthy controls.
    • Plasma ET-1 levels in patients were 6.2 ± 1.4 pg/mL (adenoma) and 6.5 ± 1.0 pg/mL (hyperplasia), compared to 8.8 ± 1.6 pg/mL in controls.
    • No significant correlations were found between ET-1 levels and other measured vasoactive hormones.

    Conclusions:

    • Circulating endothelin-1 levels do not differ between patients with primary aldosteronism and healthy individuals.
    • Endothelin-1 does not appear to play a significant role in the hypertension observed in primary aldosteronism.
    • Further research may explore other vasoactive factors in primary aldosteronism pathophysiology.